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Background: Coronary artery disease (CAD) is a major problem worldwide. Atherosclerosis and thrombosis
underlying CAD involve multiple cell types. New and useful diagnostic markers are required. MicroRNAs (miRNAs)
are a class of noncoding RNAs that posttranscriptionally regulate the gene expressions involved in various cellular
processes. Endothelial dysfunction is implicated in early processes of athero-thrombosis. Thus, it was hypothesized
that the level of vascular endothelium-enriched miRNAs would be altered in plasma samples of CAD patients.
Methods: Vascular endothelium-enriched miRNA (miR-126) level was analyzed in plasma from 31 patients with
CAD and 36 patients without CAD (qRT-PCR analysis).
Results: MiR-126 was not significantly down-regulated or up-regulated in CAD patients. Interestingly, the level of
miR-126 was significantly decreased in patients with CAD and high low-density lipoprotein (LDL) cholesterol level.
In contrast, the level of miR-126 was significantly increased when LDL cholesterol was high in patients who had risk
factors for CAD but did not have angiographically significant CAD.
Conclusion: MiR-126 was not significantly down-regulated or up-regulated in CAD patients and was not suitable
for discriminating CAD patients from patients without CAD. The oppositely-directed relationship between miR-126
and LDL cholesterol in patients with or without CAD may have significant implications for identifying a potential
role of miR-126 in cholesterol metabolism.
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Coronary artery disease (CAD) is a major problem
worldwide including Asian countries. Atherosclerosis
and thrombosis underlying CAD involves multiple cell
types [1]. Various blood markers associated with CAD
have been identified, but only a few have a diagnostic
impact or important clinical implications that affect
management [2]. Therefore, biomarkers that can assess
the risk for CAD and the early atherosclerotic process
would be desirable. Circulating microRNAs (miRNAs)
could be useful as biomarkers for various diseases* Correspondence: sfujii@phar.nagoya-cu.ac.jp
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reproduction in any medium, provided the orincluding cancer [3], acute myocardial infarction [4],
vascular diseases [5] and heart failure [6]. MiRNAs are a
class of short (20-25 nt) single-stranded noncoding
RNAs that regulate cellular functions through degrad-
ation and translational repression of mRNAs that con-
tain complementary sequences. More than 1,000 human
miRNAs are identified. In tissue miRNAs regulate the
expression of genes involved in differentiation, growth,
proliferation and apoptosis. MiRNAs regulate protein
expressions as well [7]. MiRNAs are found in tissues,
plasma and other body fluids in a stable form that is
protected from endogenous RNase activity [3]. Thus, the
signatures of miRNA in tissues and plasma may have a
potential role in diagnosis, therapeutic efficacy and prog-
nosis. In this study miRNA level in plasma of patients
with angiographically significant CAD was compared to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the patients subjected to
coronary angiography
Variables CAD (-) CAD (+) P value
n 36 31
Age (year)
61 ± 7 64 ± 11
0.11
BMI (kg/m2)
25.6 ± 2.8 24.6 ± 2.3
0.12
Systolic BP (mmHg)
134± 16 138 ± 21
0.44
Diastolic BP (mmHg)
83 ± 12 85 ± 15
0.50
Plasma Glucose (mg/dl)
114± 48 112 ± 23
0.86
HbA1c (%)
6.2 ± 1.4 5.7 ± 1.3
0.11
Total cholesterol (mg/dl)
188± 40 170 ± 44
0.09
LDL cholesterol (mg/dl)
119± 30 113 ± 38
0.48
HDL cholesterol (mg/dl)
45 ± 18 43 ± 15
0.61
Triglyceride (mg/dl)
138± 73 141 ± 89
0.88
BNP (pg/ml)
16 ± 37 105 ± 144
<0.001
NYHA class
1.0 ± 0 1.7 ± 1.0
<0.001
Data are expressed as means ± SD. A p value <0.05 was considered significant.
BMI body mass index, BP blood pressure. LDL low-density lipoprotein,
HDL high-density lipoprotein, BNP brain natriuretic peptide, NYHA New York
Heart Association.
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CAD. Because endothelial dysfunction is involved in
early processes of atherosclerosis and thrombosis [8],
vascular endothelium-enriched miRNA (miR-126) [9]
that can regulate angiogenesis was analyzed.
Materials and methods
Study population
Study participants were enrolled from FengTian Hos-
pital, consisting of 67 consecutive patients enrolled prior
to undergoing elective cardiac catheterization between
January, 2011 and October, 2011. Patients aged 40–
81 years were interviewed to collect medical history and
lifestyle habits. Risk factors were determined by phys-
ician diagnosis and/or treatment for hypertension,
hyperlipidemia and diabetes. Coronary angiograms were
evaluated independently by 28 operators who made vis-
ual estimation of luminal narrowing in multiple seg-
ments based on the AHA/ACC classification of the
coronary tree. Significant CAD was defined as at least
one major epicardial vessel with >50% stenosis. Patients
with spastic angina were not included. The study was
approved by the Institutional Review Board. All patients
provided informed consent at the time of enrollment.
RNA isolation
Venous blood samples (5 ml) were collected via antecu-
bial venipuncture in EDTA containing tubes. Blood was
rapidly centrifuged (1,200 x g for 10 min at 4°C). Super-
natant was collected and centrifuged (12,000 x g for
10 min at 4°C). Plasma was obtained and 250 μl was rap-
idly subjected to RNA extraction. MiRNA was isolated
using TRIzol LS RNA isolation kit (Invitrogen, Tokyo,
Japan) according to the manufacturer’s protocol and im-
mediately stored at -80°C.
miRNA qRT-PCR
With 10 ng total RNA miRNA reverse transcription was
performed using the TaqMan microRNA Reverse tran-
scription Kit (Applied Biosystems) at 16°C for 30 min,
42°C for 30 min and denaturation of the enzyme at 85°C
for 5 min. A Real Time PCR Assay Kit (Applied Biosys-
tems) was used to detect miRNA levels. Each reaction
was carried out in a total volume of 20 μl containing: 2
μl RT product, 1.0 μl 20x TaqMan Micro RNA assay pri-
mer, 10 μl 2× TaqMan Universal PCR Master Mix and
nuclease-free H2O to adjust the volume. The PCR reac-
tion was performed as follows; stage 1, 95°C for 10 min,
stage 2, 95°C for 15 s, 60°C for 1 min. Stage 2 was
repeated for 60 cycles. Real time PCR was performed
with the Applied Biosystems 7300 Real-Time PCR Sys-
tems at the 9600 emulation run mode. Ct values were
normalized to those of miR-16 [10-12].Statistical analysis
Statistical analyses were performed using SPSS software
(IBM, Tokyo, Japan). Values are expressed as means ±
standard deviation (SD). Continuous variables were
compared using the Mann–Whitney U test or the
Kruskall-Wallis test. For categorized values comparisons
were made by ANOVA and for post-hoc confirmation,
Bonferoni test was used. Linear regression analysis was
used to compare plasma miR-126 and LDL cholesterol,
and Kendall τb correlation was calculated to evaluate
the correlation between the data. A p value <0.05 (two
tailed) was considered significant.
Results
The clinical characteristics of patients registered are
shown in Table 1. Among 67 patients who had risk fac-
tors for CAD, 31 patients were found to have angiogra-
phically significant CAD and 36 patients were found not
to have angiographically significant CAD. Patients who
have angiographically significant CAD exhibited higher
brain natriuretic peptide (BNP) and New York Heart As-
sociation (NYHA) classification. The prevalence of
hypertension (50% in patients without CAD vs 60% in
Figure 2 The correlation between LDL cholesterol and the
circulating levels of miR-126 in patients with angiographically
significant CAD was analyzed. Circulating levels of miR-126 were
decreased in CAD patients who were showing higher levels of LDL
cholesterol (n = 31). Significant negative relationship was observed
(R2 = 0.059). Kendall τb (coefficient of correlation) = -0.253,
significance probability p = 0.047.
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different between the 2 groups. Patients who do not
have angiographically significant CAD exhibited lower
prevalence of dyslipidemia (35% vs. 55%). The lipid pro-
files were similar between the 2 groups due to medica-
tions. Patients who do not have angiographically
significant CAD exhibited less frequent use of aspirin
(25% vs. 95%), β blockers (0% vs. 85%), angiotensin-
converting enzyme inhibition/angiotensin receptor
blockers (20% vs. 90%), statin (0% vs. 90%), long acting
nitrates (0% vs. 85%), insulin (0% vs. 15%), and sulfonyl
urea (5% vs. 15%). Use of calcium channel blocker was
similar (30% vs. 20%). The miRNA levels in blood are
low and microarray approach may lack the sensitivity to
identify miRNAs that might serve as disease biomarkers.
Thus, qRT-PCR was performed on RNA isolated from
plasma of 31 patients with angiographically significant
CAD and 36 patients who had risk factors for CAD but
did not have angiographically significant CAD. The level
of miRNA that was reported to be relatively abundantly
present in plasma and tended to have different levels in
type 2 diabetes (9) was evaluated. This analysis included
miR-126 that was not significantly down-regulated in
the blood of patients with CAD as compared to patients
without CAD (Figure 1), suggesting that this miRNA is
not a marker specific for significant CAD.
There has been no report that miR-126 level can be
influenced by LDL cholesterol. Interestingly, the level of
miR-126 was significantly decreased in patients with
CAD and high LDL cholesterol level (Figure 2). In con-
trast, the level of miR-126 was significantly increased
when LDL cholesterol was high in patients who had riskFigure 1 Box plots of plasma level of miR-126 in patients with
angiographically significant CAD (n= 31) and patients without
CAD (n= 36). TaqMan miRNA assays were performed on RNA
isolated from plasma obtained from the 2 different groups. No
significant difference was observed about the plasma miR-126 levels
(p = 0 .675). The level of plasma miR-126 is normalized to miR-16.
The lines inside the boxes denote the medians. Mann-Whitey U test
or Kuskall-Wallis test was used to determine statistical significance.factors for CAD but did not have angiographically sig-
nificant CAD (Figure 3). These results may imply a link
between dysregulation of plasma miR-126 and elevated
levels of LDL cholesterol in CAD patients.
Discussion
Recent studies indicated that circulating miRNA may
become valuable biomarkers for different diseases. In
this study, it was hypothesized that the plasma miRNA
levels could predict the presence of significant CAD. AFigure 3 The correlation between LDL cholesterol and the
circulating levels of miR-126 in patients with CAD risk factors
but no significant CAD lesions was analyzed. Circulating levels of
miR-126 were increased in patients without CAD who were showing
higher levels of LDL cholesterol (n = 36). Significant positive
relationship was observed (R2 = 0.1055). Kendall τb (coefficient of
correlation) =0.245, significance probability p = 0.037.
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miRNA levels of patients with CAD compared to those
of healthy subjects [5]. In this study miR-126 was not
down-regulated in CAD patients. Care was taken to
stabilize RNA immediately after sample collection and
to facilitate storage of the samples for a relatively long
period of time without compromising RNA integrity.
The plasma concentration of miR-126 was negatively
correlated with age and NYHA class, and could be a
useful biomarker for heart failure [6]. In this study there
were no significant differences in age between the 2
groups (Table 1). Although CAD patients had slightly
higher proportion of patients with high NYHA class, the
miR-126 levels did not differ. Frequent use of medica-
tions in CAD patients did not affect miR-126 levels,
either.
mRNA profiling of blood or peripheral mononuclear
cells has been applied to cardiovascular diseases [13],
and a relationship has been identified between mRNA
levels in whole blood and extent of CAD. The present
study extends this work by providing insight into the
plasma level of miR-126 that is potentially involved in
regulating CAD. Because the present analysis included
relatively small sample size and microarray method may
exhibit reduced sensitivity, sensitive qRT-PCR was used.
The level of miR-126 was normalized to that of miR-16,
which is highly and consistently expressed across blood
samples from patients and controls [10-12,14]. Analysis
with qRT-PCR of plasma samples revealed similar levels
of miR-126 with or without CAD. Two possible reasons
may exist. Plasma miR-126 profile likely reflects extra-
cellular miRNAs and may not fully reflect intracellular
miRNAs levels. It is also likely that the patients without
CAD could have subclinical vascular inflammation and
other pathophysiological alterations similar to those of
the CAD patients. Further analysis of plasma miR-126
levels in age-matched healthy subjects are planned in
the future.
The mechanism of decreased level of circulating miR-
126 in patients with CAD in proportion to the increase
in LDL cholesterol remains unclear. Although miRNA is
known to be associated with high-density lipoprotein
(HDL) cholesterol [15], HDL levels were similar between
the 2 groups. It has been hypothesized that the levels of
circulating miRNAs are decreased in vascular diseases
because they have been taken up into atherosclerotic
lesions [5]. The levels of circulating miRNAs may be
affected by multiple factors including transcription, pro-
cessing and stability of the miRNAs within circulating
cells, as well as the ability of these cells to release miR-
NAs into the plasma. Circulating miRNAs may be deliv-
ered to cells in the heart or blood vessels through
microvesicles, exosomes or apoptotic bodies [16]. Be-
cause the present study assessed miR-126 levels inplasma, the present findings may reflect the changes in
miRNA transcription or processing as well as the release
from the circulating cells. It remains to be determined
whether down-regulation of miR-126 in CAD patients is
directly involved in inflammation or a compensatory re-
sponse to this process. Based on the observed changes
in miR-126 level in association with LDL cholesterol,
the circulating miRNA levels may reflect a compensa-
tory response to inflammation under hyperlipidemic
background. During the course of the vascular disease
processes endothelial miR-126 may be depleted and
plasma levels may start to decrease [9]. The vascular
miR-126 is consumed during transcoronary passage
[17]. Certain miRNAs are reported to regulate choles-
terol efflux [18,19]. However, miR-126 is not predicted
to target component(s) of LDL. Although statin was
frequently used in CAD patients in this study, statin
does not influence miR-126 in endothelial progenitor
cells [20]. Further studies are necessary to explore the
underlying mechanisms potentially linking LDL choles-
terol and circulating miR-126 levels in patients with
CAD.
Conclusion
Although the potential utility of plasma levels of miR-
126 as biomarkers for CAD was not demonstrated, the
present study provided insight into the potential role of
miR-126 in cholesterol metabolism. Further elucidation
of the role that miR-126 plays in cholesterol metabolism
may contribute to the understanding of the disease
process of atherosclerosis and thrombosis.
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